Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an angiogenic inducer as well as a mediator of vascular permeability. The biological effects of VEGF are mediated by two tyrosine kinase receptors, Flt-1 (VEGFr-1) and KDR (VEGFR-2). VEGF is essential for developmental angiogenesis and is also required for female reproductive functions and endochondral bone formation. Substantial evidence also implicates VEGF in tumors and intraocular neovascular syndromes. Currently, several clinical trials are ongoing to test the hypothesis that inhibition of VEGF activity may be beneficial for these conditions.

Keywords:
Angiogenesis, Apoptosis, Endothelium, Retinopathy, Tumor growth, Tyrosine kinases, Vascular endothelial growth factor
1.
Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.
2.
Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794–814.
3.
Korpelainen EI, Alitalo K: Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998;10:159–164.
4.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306–1309.
5.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841–844.
6.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen H, Aiello LM, Ferrara N, King GL: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487.
7.
Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457–10461.
8.
Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359–1364.
9.
Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851–858.
10.
Conn G, Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM, Hope DA, Thomas KA: Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990;87:2628–2632.
11.
Plouet J, Schilling J, Gospodarowicz D: Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989;8:3801–3808.
12.
Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Malecaze F, Plouet J: Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995;164:385–394.
13.
Oberg-Welsh C, Sandler S, Andersson A, Welsh M: Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro. Mol Cell Endocrinol 1997;126:125–132.
14.
Sondell M, Lundborg G, Kanje M: Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19:5731–5740.
15.
Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024–1028.
16.
Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273:13313–13316.
17.
Gerber HP, McMurtrey A, Kowalski, J, Yan M, Keyt BA, Dixit V, Ferrara N: VEGF regulates endothelial cell survival by the PI 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336–30343.
18.
Benjamin LE, Golijanin D, Itin A, Pode, D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159–165.
19.
Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996;93:14765–14770.
20.
Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oostuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A, Poelmann R, Lupu F, Herbert JM, Collen D, Dejana E: Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98:147–157.
21.
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985.
22.
Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039.
23.
Dvorak HF: Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650–1659.
24.
Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM: Fibrin containing gels induce angiogenesis: Implications for tumor stroma generation and wound healing. Lab Invest 1987;57:673–686.
25.
Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA: Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915–924.
26.
Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1990;8:519–527.
27.
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989–991.
28.
Terman BI, Dougher Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579–1586.
29.
Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66–70.
30.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–66.
31.
Waltenberger J, Claesson Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988–26995.
32.
Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M: A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995;10:135–147.
33.
Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996;271:5638–5646.
34.
Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646–25654.
35.
Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998;4:9349–9354.
36.
Fong GH, Zhang L, Bryce DM, Peng J: Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999;126:3015–3025.
37.
Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N: A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J 2000;19:4064–4073.
38.
Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336–3343.
39.
Wang H, Keiser JA: Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ Res 1998;83:832–840.
40.
Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735–745.
41.
Fujisawa H, Kitsukawa T: Receptors for collapsin/semaphorins. Curr Opin Neurobiol 1998;8:587–592.
42.
Luo Y, Jan LY, Jan YN: Collapsin: A protein in brain that induces collapse and paralysis of neuronal growth cones. Cell 1993;75:217–227.
43.
Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M: Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999;146:233–242.
44.
Wang HU, Chen ZF, Anderson DJ: Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93:741–753.
45.
Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R: Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, sprouting angiogenesis. Genes Dev 1999;13:295–306.
46.
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435–439.
47.
Ferrara N, Carver Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439–442.
48.
Carmeliet P, Ng Y-S, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard J-C, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D’Amore PA, Shima DT: Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelila growth factor isoforms VEGF164 and VEGF188. Nat Med 1999;5:495–502.
49.
Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano PY, Gu Y, Hickey R, Nath AK, Dalton N, Peterson KL, Ross J, Chien KR, Ferrara N: A cardiac myocyte VEGF paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 2001;98:5780–5785.
50.
Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller G-A, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N: VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149–1159.
51.
Kuhn R, Schwenk F, Aguet M, Rajewsky K: Inducible gene targeting in mice. Science 1995;269:1427–1429.
52.
Poole AR: Cartilage: Molecular Aspects. Boca Raton, CRC Press, 1991, pp 179–211.
53.
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623–628.
54.
Carlevaro MF, Cermelli S, Cancedda R, Descalzi Cancedda F: Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: Auto-paracrine role during endochondral bone formation. J Cell Sci 2000;113:59–69.
55.
Bassett DL: The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am J Anat 1943;73:251–278.
56.
Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG: Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998;78:1385–1394.
57.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegend SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997;277:55–60.
58.
Phillips HS, Hains J, Leung DW, Ferrara N: Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 1990;127:965–967.
59.
Ravindranath N, Little-Ihrig L, Phillips HS, Ferrara N, Zeleznik AJ: Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 1992;131:254–260.
60.
Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E: Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis. J Clin Invest 1993;91:2235–2243.
61.
Cullinan-Bove K, Koos RD: Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 1993;133:829–837.
62.
Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N: The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 1996;15:4919–4927.
63.
Ferrara N, Chen H, Davis-Smyth T, Gerber H-P, Nguyen T-N, Peers D, Chisholm V, Hillan KJ, Schwall RH: Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336–340.
64.
Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O’Neill CA: Preclinical safety evaluation of rhuMAb VEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999;27:78–86.
65.
Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, Bicknell R: Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 2000;141:995–1000.
66.
Engel T, Jewelewicz R, Dyrenfurth I, Speroff L, Vande Wiele RL: Ovarian hyperstimulation syndrome: Report of one case with notes on pathogenesis and treatment. Am J Obstet Gynecol 1972;112:1052–1057.
67.
Haning RJ, Strawn E, Nolten W: Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 1985;166:220–224.
68.
McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV, Connolly DT, Robertson DM: Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235–269.
69.
Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, Pedram A: Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998;102:1978–1985.
70.
Kobayashi H, Okada Y, Asahina T, Gotoh J, Terao T: The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome. J Mol Endocrinol 1998;20:363–374.
71.
Aboulghar MA, Mansour RT, Serour GI, El Helw BA, Shaarawy M: Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol 1999;87:81–85.
72.
Ide AG, Baker NH, Warren SL: Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 1939;42:891–899.
73.
Algire GH, Chalkley HW: Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73–85.
74.
Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182–1186.
75.
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15–24.
76.
Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–4599.
77.
Prewett M, Huber J, Li Y, Santiago A, O’Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res 1999;59:5209–5218.
78.
Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540–3545.
79.
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178–2189.
80.
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF: ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000;60:970–975.
81.
DeVore R, Herbst RS, Langer CJ, Kelly K, Gaudreault J, Holmgren E, Novotny WF, Kabbinavar FA: A randomized Phase II Trial Comparing rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) plus Carboplatin/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV NSCLC. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, 2000.
82.
Bergsland E, Fehrenbacher L, Meropol NJ, Novotny WF, Gaudreault J, Lieberman GFK: A Randomized Phase II Trial Comparing rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) plus 5-Fluorouracil/Leucovorin (FU/LV) to FU/LV Alone in Patients with Metastatic Colorectal Cancer. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, 2000.
83.
Sledge G, Miller K, Novotny W, Gaudreault J, Ash M, Colbeigh M: A Phase II Trial of Single-Agent rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelila Growth Factor) in Patients with Relapsing Metastatic Breast Cancer. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, 2000.
84.
Rosen PJ, Amado R, Hecht JR, Chang D, Mulay M, Parson M, Laxa B, Brown J, Cropp G, Hannah A, Rosen L: A Phase I/II Study of SU5416 in Combination with 5-FU/Leucovorin in Patients with Metastatic Colorectal Cancer. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, 2000.
85.
Bautz F, Rafii S, Kanz L, Mohle R: Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. Exp Hematol 2000;28:700–706.
86.
Kabrun N, Buhring HJ, Choi K, Ullrich A, Risau W, Keller G: Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 1997;124:2039–2048.
87.
Ziegler BL, Valtieri M, Porada GA, De Maria R, Muller R, Masella B, Gabbianelli M, Casella I, Pelosi E, Bock T, Zanjani ED, Peschle C: KDR receptor: A key marker defining hematopoietic stem cells. Science 1999;285:1553–1558.
88.
Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150–4166.
89.
Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511–521.
90.
Bellamy WT, Richter L, Frutiger Y, Grogan TM: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728–733.
91.
Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427–1434.
92.
Fielder W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK: Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997;11:1234–1237.
93.
Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915–25919.
94.
Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R: Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800–805.
95.
Garner A: Vascular Diseases, ed 2. New York, Dekker, 1994.
96.
Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR: Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855–868.
97.
Kvanta A, Algvere PV, Berglin L, Seregard S: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929–1934.
98.
Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB: Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865–881.
99.
van Bruggen N, Thibodeaux H, Palmer JT, Cairns B, Tumas D, Gerlai R, Williams S-P, van Lookeren Campagne M, Ferrara N: VEGF antagonism reduces cerebral edema formation and tissue damage following ischemic-reperfusion injury in the mouse brain. J Clin Invest 1999;104:1613–1620.
100.
Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U: Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998;95:11709–11714.
101.
Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, Mould A, Cahill MM, Tonks ID, Grimmond SM, Townson S, Wells C, Little M, Cummings MC, Hayward NK, Kay GF: Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, impaired recovery from cardiac ischemia. Circ Res 2000;86:E29–35.
102.
Henry T, Annex BH, Azrin MA, McKendall GR, Willerson JT, Hendel RC, Giordano FJ, Klein R, Gibson CM, Berman DS, Luce CA, McCluskey ER: Double Blind, Placebo Controlled Trial of Recombinant Human Vascular Endothelial Growth Factor: The VIVA Trial. J Am Coll Cardiol 1999;33/2(suppl A):384A, 874.
103.
Ogilvie C, Lee M, Miclau T, Hu D, Werb Z, Helms J: The role of angiogenesis in bone regeneration. 46th Annual Meeting of the Orthopedic Research Society, Orlando, 2000.
© 2001 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.